

Revision date: 15-Jul-2014 Version: 4.0 Page 1 of 9

# 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Clindamycin Palmitate Hydrochloride for Oral Solution

Trade Name: Cleocin Pediatric Flavored Granules; Dalacin C Flavored Granules; Sobelin

Synonyms: Dalacin C Syrup

Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as antibiotic agent

**Details of the Supplier of the Safety Data Sheet** 

Pfizer Inc Pfizer Ltd
Pfizer Pharmaceuticals Group Ramsgate Road
235 East 42nd Street Sandwich, Kent
New York, New York 10017 CT13 9NJ
1-800-879-3477 United Kingdom

United Kingdom +00 44 (0)1304 616161

Emergency telephone number: Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300 International CHEMTREC (24 hours): +1-703-527-3887

Contact E-Mail: pfizer-MSDS@pfizer.com

## 2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

**GHS - Classification** 

Skin Sensitization: Category 1

**US OSHA Specific - Classification** 

Physical Hazard: Combustible Dust

**EU Classification:** 

EU Indication of danger: Harmful

R43 - May cause sensitization by skin contact.

**Label Elements** 

Signal Word: Warning

Hazard Statements: H317 - May cause an allergic skin reaction

May form combustible dust concentrations in air

Material Name: Clindamycin Palmitate Hydrochloride for Oral Page 2 of 9

Solution

Revision date: 15-Jul-2014 Version: 4.0

**Precautionary Statements:** P261 - Avoid breathing dust/fume/gas/mist/vapors/spray

P272 - Contaminated work clothing should not be allowed out of the workplace P280 - Wear protective gloves/protective clothing/eye protection/face protection

P302+ P352 - IF ON SKIN: Wash with plenty of soap and water

P333 + P313 - If skin irritation or rash occurs: Get medical advice/attention P321 - Specific treatment (see supplemental first aid instructions on this label)

P363 - Wash contaminated clothing before reuse

P501 - Dispose of contents/container in accordance with all local and national regulations



Other Hazards
Australian Hazard Classification
(NOHSC):

Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which

requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases.

Your needs may vary depending upon the potential for exposure in your workplace.

# 3. COMPOSITION / INFORMATION ON INGREDIENTS

## Hazardous

Ingredient	CAS Number	EU	<b>EU Classification</b>	GHS	%
		EINECS/ELINCS		Classification	
		List			
Clindamycin Hydrochloride Palmitate	25507-04-4	Not Listed	Xi;R43	Skin Sens.1 (H317)	3.8
Sucrose	57-50-1	200-334-9	Not Listed	Not Listed	*

Ingredient	CAS Number	EU	EU Classification	GHS	%
		EINECS/ELINCS		Classification	
		List			
Simethicone	8050-81-5	Not Listed	Not Listed	Not Listed	*
Cherry flavor, artificial	NOT ASSIGNED	Not Listed	Not Listed	Not Listed	*
Poloxalene	9003-11-6	Not Listed	Not Listed	Not Listed	*
Dextrin	9004-53-9	232-675-4	Not Listed	Not Listed	*
Ethylparaben	120-47-8	204-399-4	Not Listed	Not Listed	*

Additional Information: \* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this

mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

Material Name: Clindamycin Palmitate Hydrochloride for Oral Page 3 of 9

Solution

Revision date: 15-Jul-2014 Version: 4.0

-----

## 4. FIRST AID MEASURES

**Description of First Aid Measures** 

**Eye Contact:** Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention

immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

**Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of For information on potential signs and symptoms of exposure, See Section 2 - Hazards

**Exposure:** Identification and/or Section 11 - Toxicological Information.

Medical Conditions None known

Aggravated by Exposure:

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

## 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

**Hazardous Combustion** Formation of toxic gases is possible during heating or fire.

**Products:** 

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

# 6. ACCIDENTAL RELEASE MEASURES

### Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

#### **Environmental Precautions**

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

#### Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Contain the source of spill if it is safe to do so. Collect spilled material by a method that

Collecting: controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of

dry solids. Clean spill area thoroughly.

**Additional Consideration for** 

Large Spills:

Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

## 7. HANDLING AND STORAGE

### **Precautions for Safe Handling**

Material Name: Clindamycin Palmitate Hydrochloride for Oral Page 4 of 9

**Solution** 

Revision date: 15-Jul-2014 Version: 4.0

# 7. HANDLING AND STORAGE

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

**Storage Conditions:** Store as directed by product packaging.

Specific end use(s): No data available

# 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

#### **Control Parameters**

Refer to available public information for specific member state Occupational Exposure Limits.

#### **Clindamycin Hydrochloride Palmitate**

Pfizer OEL TWA-8 Hr: 100µg/m³, (as free base)

## Sucrose

**ACGIH Threshold Limit Value (TWA)** 10 ma/m<sup>3</sup> 10 mg/m<sup>3</sup> Australia TWA 10 mg/m<sup>3</sup> **Belgium OEL - TWA Bulgaria OEL - TWA** 10.0 mg/m<sup>3</sup> Estonia OEL - TWA 10 mg/m<sup>3</sup> France OEL - TWA 10 mg/m<sup>3</sup> **Ireland OEL - TWAs** 10 mg/m<sup>3</sup>  $5 \text{ mg/m}^3$ Latvia OEL - TWA 10 mg/m<sup>3</sup> Lithuania OEL - TWA 15 mg/m<sup>3</sup> **OSHA - Final PELS - TWAs:** Portugal OEL - TWA 10 mg/m<sup>3</sup> 6 mg/m<sup>3</sup> Slovakia OEL - TWA 10 mg/m<sup>3</sup> Spain OEL - TWA

**Exposure Controls** 

**Engineering Controls:** Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne

contamination levels below the exposure limits listed above in this section.

Personal Protective Refer to applicable national standards and regulations in the selection and use of personal

**Equipment:** protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk

processing operations.

**Eyes:** Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and

for bulk processing operations.

**Respiratory protection:** Respiratory protection is recommended as a precaution to minimize exposure when handling

this material in bulk.

**Molecular Weight:** 

Mixture

Material Name: Clindamycin Palmitate Hydrochloride for Oral Page 5 of 9

Solution

Revision date: 15-Jul-2014 Version: 4.0

# 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:GranulesColor:No data available.Odor:No data available.Odor Threshold:No data available.

Molecular Formula: Mixture

Solvent Solubility:
Water Solubility:
Solubility:
PH:
No data available
Solubile: Water
PH:
No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)

Clindamycin Hydrochloride Palmitate

No data available

Sucrose

No data available Cherry flavor, artificial No data available

**Dextrin** 

No data available

Ethylparaben
No data available

Simethicone
No data available
Poloxalene

No data available

**Decomposition Temperature (°C):** No data available.

Evaporation Rate (Gram/s):

Vapor Pressure (kPa):

Vapor Density (g/ml):

Relative Density:

Viscosity:

No data available
No data available
No data available
No data available

Flammablity:

Autoignition Temperature (Solid) (°C):

Flammability (Solids):

Flash Point (Liquid) (°C):

Upper Explosive Limits (Liquid) (% by Vol.):

Lower Explosive Limits (Liquid) (% by Vol.):

No data available
No data available

# 10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

**Possibility of Hazardous Reactions** 

Oxidizing Properties: No data available

**Conditions to Avoid:** Fine particles (such as dust and mists) may fuel fires/explosions. **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition No data available

**Products:** 

Material Name: Clindamycin Palmitate Hydrochloride for Oral Page 6 of 9

Solution

Revision date: 15-Jul-2014 Version: 4.0

# 11. TOXICOLOGICAL INFORMATION

#### Information on Toxicological Effects

**General Information:** The information included in this section describes the potential hazards of the individual

ingredients.

Known Clinical Effects: Individuals sensitive to this material or other materials in its chemical class may develop

allergic reactions. Pseudomembranous colitis (manifested by watery diarrhea, urge to defecate, abdominal cramps, low-grade fever, bloody stools, and abdominal pain) may also

occur. Effects on blood and blood-forming organs have also occurred.

#### Acute Toxicity: (Species, Route, End Point, Dose)

## Clindamycin Hydrochloride Palmitate

Rat Oral LD 50 > 5000 mg/kg

Rat Para-periosteal LD 50 > 5000mg/kg Rat Intraperitoneal LD 50 > 2500mg/kg Mouse Oral LD 50 > 5000mg/kg

Mouse Intravenous LD 50 > 5000mg/kg

**Sucrose** 

Rat Oral LD50 29.7 g/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

## Clindamycin Hydrochloride Palmitate

6 Month(s) Rat Oral600 mg/kg/day NOAEL No effects at maximum dose 6 Month(s) Dog Oral 300 mg/kg/day NOAEL No effects at maximum dose

## Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

### Clindamycin Hydrochloride Palmitate

Reproductive & Fertility Rat Oral 300 mg/kg/day NOAEL Negative, No effects at maximum dose

Embryo / Fetal Development Mouse Oral 600 mg/kg/day NOAEL Not Teratogenic, No effects at maximum dose

## Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

## Clindamycin Hydrochloride Palmitate

Bacterial Mutagenicity (Ames) Salmonella Negative

Micronucleus Rat Negative

**Sucrose** 

Bacterial Mutagenicity (Ames) Salmonella Negative

**Carcinogen Status:**None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Material Name: Clindamycin Palmitate Hydrochloride for Oral Page 7 of 9

Solution

Revision date: 15-Jul-2014 Version: 4.0

# 12. ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been thoroughly investigated. Releases to the environment

should be avoided.

**Toxicity:** No data available

Persistence and Degradability: No data available

**Bio-accumulative Potential:** No data available

Mobility in Soil: No data available

### 13. DISPOSAL CONSIDERATIONS

**Waste Treatment Methods:** Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental

releases. This may include destructive techniques for waste and wastewater.

# 14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

## 15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications WHMIS hazard class: Class D, Division 2, Subdivision A



Clindamycin Hydrochloride Palmitate **CERCLA/SARA 313 Emission reporting** 

Not Listed

Material Name: Clindamycin Palmitate Hydrochloride for Oral Page 8 of 9

Solution

Revision date: 15-Jul-2014 Version: 4.0

15. REGULATORY INFORMATION	
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed
Simethicone	
	No. 1 intend
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed
Cherry flavor, artificial	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed
Poloxalene	Not Listed
CERCLA/SARA 313 Emission reporting	
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed
Dextrin	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the	Present
obligations of Register:	
EU EINECS/ELINCS List	232-675-4
Sucrose	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the	Present
obligations of Register:	1 1000111
EU EINECS/ELINCS List	200-334-9

Not Listed

Not Listed

Present

Present

204-399-4

# **16. OTHER INFORMATION**

Australia (AICS):

**California Proposition 65** 

**EU EINECS/ELINCS List** 

Ethylparaben

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

**CERCLA/SARA 313 Emission reporting** 

Inventory - United States TSCA - Sect. 8(b)

Material Name: Clindamycin Palmitate Hydrochloride for Oral Page 9 of 9

Solution

Revision date: 15-Jul-2014 Version: 4.0

Sensitization, skin-Cat.1; H317 - May cause an allergic skin reaction

Xi - Irritant

R43 - May cause sensitization by skin contact.

**Data Sources:** Publicly available toxicity information. Safety data sheets for individual ingredients. Pfizer

proprietary drug development information.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 1 - Identification of the

Substance/Preparation and the Company/Undertaking.

Revision date: 15-Jul-2014

Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

**End of Safety Data Sheet**